复方皂刺汤对顺铂联合吉西他滨抑制非小细胞肺癌生长的作用及其机制研究

doi:10.3969/j.issn.1004-616x.2022.05.006

Abstract

Abstract: OBJECTIVE: To investigate effects from Zaoci decotion in combinations with cisplatin and gemcitadine on growth inhibition of non-small cell lung cancers.METHODS: Fifty SPF-grade BALB/c nude mice were inoculated with A549 cell suspension in the axilla of the right forelimb against the back and used as a non-small cell lung cancer model.After successful modeling,inoculated mice were randomly divided into several groups:model,Zaoci decotion,gemcitabine combined with cisplatin (GP),cisplatin,and Zaoci decotion combined with GP.The model group was gavaged with saline (0.01 mL/g) per day;Zaoci decotion group gavaged with daily saponin soup (1 mL/mouse);GP group intraperitoneal injection with cisplatin (2 mg/kg) and gemcitabine (50 mg/kg) once every 3 days;cisplatin group intraperitoneal injection with cisplatin (2 mg/kg) for 1 time every 3 days;Zaoci decotion combined with GP regimen group daily gavage with Zaoci decotion (1 mL/mouse) and intraperitoneal injection with cisplatin (2 mg/kg) and gemcitabine (50 mg/kg) every 3 days.A total of 21 d of treatment was administered to each group.Tumor diameters were measured by vernier calipers at 3 d,7 d,14 d and 21 d of administrations;their weights were recorded after execution of the mice;tumor cell apoptoses were observed by TUNEL staining;tumor tissue Ki67,CD31,α-SMA and VEGF expressions were detected by immunohistochemistry;serum IL-4,IL-6 and TNF-α concentrations were detected by ELISA;tumor tissue Bax,Bcl-2 and Caspase-3 protein expressions were detected by Western blot.RESULTS: On the 21st day of administration,compared with the model group,tumor volumes and tumor weights in the Zaoci decotion,GP,cisplatin,and Zaoci decotion combined with GP groups were reduced significantly.The tumor volumes and tumor weights of the Zaoci decotion combined with GP group were the smallest (P<0.05).The apoptosis rates,Bax and Caspase-3 protein expressions were significantly higher,and Ki67 and Bcl-2 protein expressions were significantly lower in the Zaoci decotion combined with GP compared with the model group,the Zaoci decotion,the GP,and the cisplatin groups (P<0.05).Compared with the model group,the Zaoci decotion and the GP groups showed significantly lower IL-6 and TNF-α contents,and expressions of CD31,α-SMA and VEGF proteins (P<0.05).The contents of IL-4 were significantly higher in the Zaoci decotion combined with GP group (P<0.05).CONCLUSION: Zaoci decotion showed significant enhancing effects on the growth inhibition of non-small cell lung cancer by cisplatin combined with gemcitabine.The mechanism may be related to the inhibition of angiogenesis and induction of apoptosis.

Key words: non-small cell lung cancer, compound Zaoci decotion, cisplatin, gemcitabine, angiogenesis, apoptosis

CLC Number:

R734.2

QI Jiankao, TANG Xiao, SUN Shihui, KOU Yanfang, CUI Zhiqin. Growth inhibition of non-small cell lung cancers by Zaoci decotion in combination with cisplatin and gemcitabine[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 366-372,403.

References

[1] JONNA S, SUBRAMANIAM D S. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC):an update[J]. Discov Med, 2019, 27(148):167-170.
[2] BRODERICK S R. Adjuvant and neoadjuvant immunotherapy in non-small cell lung cancer[J]. Thorac Surg Clin, 2020, 30(2):215-220.
[3] WEI J X, YU Y Y, LI Y N, et al. Pharmacokinetics, tissue distribution and excretion of 6-O-demethylmenisporphine, a bioactive oxoisoaporphine alkaloid from Menispermi Rhizoma, as determined by a HPLC-MS/MS method[J]. J Chromatogr B, 2020, 1156:122297.
[4] KASYMJANOVA G, TRAN A T, COHEN V, et al. The use of a standardized Chinese herbal formula in patients with advanced lung cancer:a feasibility study[J]. J Integr Med, 2018, 16(6):390-395.
[5] 张羽飞,朱鸿帆,吴申,等.复方皂刺汤联合PP方案治疗晚期非小细胞肺癌疗效及安全性分析[J].陕西中医, 2020, 41(1):60-62.
[6] EGUCHI R, WAKABAYASHI I. HDGF enhances VEGFdependent angiogenesis and FGF-2 is a VEGF-independent angiogenic factor in non-small cell lung cancer[J]. Oncol Rep, 2020:44(1):14-28.
[7] GRIESINGER F, KOROL E E, KAYANIYIL S, et al. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer:a meta-analysis[J]. Lung Cancer, 2019, 135:196-204.
[8] LI T M, YU Y H, TSAI F J, et al. Characteristics of Chinese herbal medicine usage and its effect on survival of lung cancer patients in Taiwan[J]. J Ethnopharmacol, 2018, 213:92-100.
[9] NAGASAKA M, GADGEEL S M. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer[J]. Expert Rev Anticancer Ther, 2018, 18(1):63-70.
[10] 黃南光.复方皂刺汤联合化疗治疗晚期非小细胞肺癌临床疗效观察[D].南京:南京中医药大学, 2018.
[11] WU J Y, WENG Y S, CHIOU Y C, et al. Induction of apoptosis and inhibition of EGFR/NF-κB signaling are associated with regorafenib-sensitized non-small cell lung cancer to cisplatin[J]. In Vivo, 2021, 35(5):2569-2576.
[12] 李亮.华蟾素联合吉西他滨对人NSCLC细胞的作用研究[D].泸州:西南医科大学, 2016.
[13] YANG S C, ZHANG D W, SHEN N, et al. Dihydroartemisinin increases gemcitabine therapeutic efficacy in ovarian cancer by inducing reactive oxygen species[J]. J Cell Biochem, 2019, 120(1):634-644.
[14] SAHAI V, CATALANO P J, ZALUPSKI M M, et al. Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma:a phase 2 clinical trial[J]. JAMA Oncol, 2018, 4(12):1707-1712.
[15] SYRIOS J, KOUROUSSIS C, KOTSAKIS A, et al. Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer:a phase I study[J]. Minerva Ginecol, 2019, 71(3):182-190.
[16] HE S W, ZHANG Y, CHEN L, et al. Gemcitabine synergizes with cisplatin to inhibit nasopharyngeal carcinoma cell proliferation and tumor growth[J]. FASEB J, 2021, 35(10):e21885.
[17] GHASEMI A, KHANZADEH T, ZADI HEYDARABAD M, et al. Evaluation of BAX and BCL-2 gene expression and apoptosis induction in acute lymphoblastic leukemia cell line CCRFCEM after high-dose prednisolone treatment[J]. Asian Pac J Cancer Prev, 2018, 19(8):2319-2323.
[18] NANGIA V, SIDDIQUI F M, CAENEPEEL S, et al. Exploiting MCL1 dependency with combination MEK+MCL1 inhibitors leads to induction of apoptosis and tumor regression in KRASmutant non-small cell lung cancer[J]. Cancer Discov, 2018, 8(12):1598-1613.
[19] ZHANG W, CHEN H, LIU D L, et al. Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets[J]. Int J Oncol, 2013, 42(4):1189-1196.
[20] MAO Z J, XU B T, HE L X, et al. PVT1 promotes angiogenesis by regulating miR-29c/vascular endothelial growth factor (VEGF) signaling pathway in non-small-cell lung cancer (NSCLC)[J]. Med Sci Monit, 2019, 25:5418-5425.
[21] WATANABE H, ICHIHARA E, KAYATANI H, et al. VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogenedriven non-small-cell lung cancers[J]. Cancer Sci, 2021, 112(5):1853-1864.
[22] LIN B Q, ZENG Z Y, YANG S S, et al. Dietary restriction suppresses tumor growth, reduces angiogenesis, and improves tumor microenvironment in human non-small-cell lung cancer xenografts[J]. Lung Cancer, 2013, 79(2):111-117.
[23] HOU Y J, JIA H M, CAO Y H, et al. LncRNA EPIC1 promotes tumor angiogenesis via activating the Ang2/Tie2 axis in non-small cell lung cancer[J]. Life Sci, 2021, 267:118933.
[24] 刘天舒,戎宽,谭小宁,等.臭牡丹复方对肺癌大鼠血清中TGF-β1、IL-4、IL-10水平的影响[J].湖南中医杂志, 2017, 33(2):129-131.
[25] 梁瑞宁,施旻,占诗艳,等.平冲降逆方对裸鼠人子宫膜异位症模型凋亡及TNF-α、IL-8表达的影响[J].中国中西医结合杂志, 2017, 37(8):979-984.

Growth inhibition of non-small cell lung cancers by Zaoci decotion in combination with cisplatin and gemcitabine

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHANG Yue, WANG Yaoyi, WU Xueliang, ZHANG Zhisheng, YANG Xiuming, JIANG Yang, QIAO Zhifei, LIANG Wanping, XUE Jun. The combination of ¹²⁵I particles and AZD1152 efficiently inhibited proliferation and promoted apoptosis of a triple negative breast cancer cell line [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(4): 295-299,306.
[2]	ZHAO Chenqian, XU Anqi, AI Duo, KONG Deqin, ZHANG Xiaodi, LI Wenli, HAI Chunxu, LIU Jiangzheng. Effects of Mito-TEMPO treatment on nitrogen mustard-induced cytotoxicity in BEAS-2B cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(3): 161-168.
[3]	ZHANG Qi, LIU Yujun, ZHUANG Xibing, QIAO Tiankui. Fuzi extracts on proliferation and radiosensitization of lung cancer A549 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(3): 227-232.
[4]	LI Boru, QIN Shuangjian, GUAN Lan, LI Runbing, CAI Ying, PU Jiening, ZENG Ming, XIAO Fang, XU Xinyun. Effects of PM_2.5 on oxidative damage and apoptosis in HK-2 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 360-364.
[5]	LIU Xiaoxia, LI Weixia, LI Zhijia, SU Zhenjun, DUAN Xiaohui, HAN Weiwen, WANG Yunxiao, HE Xiaolei, Lu Linlin, JIA Jinhai. Correlations between glutathione peroxidase in serum and clinicopathological outcomes of advanced non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 286-290,295.
[6]	HUANG Xiaohua, NIU Yongdong, SHI Ganggang. Inhibitory effects and mechanisms of nuclear receptor FXR activation in cervical cancer cell line CaSki [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 302-306.
[7]	WANG Xikai, MENG Qinghe, GAO Yanlu. miR-223-3p negatively regulated ECT2 to induce apoptosis in non-small cell lung cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 187-192.
[8]	LI Boru, QIN Shuangjian, LI Runbing, CAI Ying, ZHENG Kai, ZENG Ming, XIAO Fang, XU Xinyun. Effects of p38MAPK gene on PM_2.5-induced expression of oncogenes and apoptosis genes in HK-2 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(2): 129-135,142.
[9]	MA Shunpeng, WANG Quankai, WANG Miao, SONG Jiayang, WUHAN Baolier, XIE Guangyun, XU Jianning. Long non-coding RNA regulates apoptosis during glycidyl methacrylate-induced malignant transformation of 16HBE cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 1-5,31.
[10]	LI Boru, QIN Shuangjian, LI Runbing, CAI Ying, ZHENG Kai, WANG Bingyu, ZENG Ming, XIAO Fang, XU Xinyun. Effects of PM_2.5 exposure on expression of oncogenes and apoptosis genes in human renal epithelial cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 6-11.
[11]	HUANG Lili, ZHANG Mengyun, LIU Keliang, PANG Dingguo, LIU Lida, XU Peiyu. Hepatotoxicity of 2,4-dichlorophenoxyacetic acid in young SD rats [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 22-27.
[12]	CUI Zhaoyang, LI Suna, JIANG Xuqian, WANG Yidan, HOU Liying. Activation of the TRAIL death receptor by apigenin for induction of apoptosis in the gastric cancer SGC-7901 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 32-36.
[13]	LAN Li, CHEN Haili, XU Lei. Mechanism of RBMS3-S3 on the proliferation, apoptosis and invasion of cervical cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 438-443.
[14]	LIU Peng, BAI Yixiao. Effect of miR-29a on proliferation and migration of human gastric cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 452-456,463.
[15]	LIU Xiaoxia, LI Weixia, SU Zhenjun, JIA Jinhai, DUAN Xiaohui, LI Zhijia, HE Xiaolei, L Linlin, LIU Rui, WANG Yunxiao. Analyses of clinicopathological characteristics and curative effect of combined radio-with chemo-therapy for advanced non-small cell lung cancer with superoxide dismutase activity in serum [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 350-354.